ADORA2A and Parkinson disease: Istradefylline, a selective A2AR antagonist and an approved anti-PD drug in Japan, efficiently crosses blood-brain barrier, binds to A2AR with high affinity, and potentiates L-DOPA (a dopamine precursor; standard of PD therapeutics) activity [19].